Amy Tseng is TissueTech’s President and Chief Executive Officer and a member of the company’s Board of Directors. Amy co-founded BioTissue in 1997 and TissueTech in 2001 with the vision of commercializing cryopreserved amniotic membrane as a platform technology for the treatment of ocular surface diseases. Since its inception, Amy has presided over this mission, building BioTissue into the industry leader in this sector and spearheading the founding of Amniox Medical to expand the Company’s technology into other healthcare sectors. She has guided the company through impressive levels of annual growth. Prior to founding BioTissue, Amy spent 10 years with the big five accounting firms, Ernst & Young and Price Waterhouse. Amy holds a Master of Business Administration from the University of Southern California.